ASSESSMENT OF DYSLIPIDEMIA IN TYPE II DIABETES MELLITUS WITH SECONDARY COMPLICATIONS
Objective: The main aim of the present study was to investigate the levels of lipid and lipoproteins in causing secondary microvascular complications in diabetic patients. Patients of Type II diabetes mellitus are highly susceptible to various complications due to long-term persistence of hyperglycemic state in the body. Thus, it is imperative to study the effect of hyperglycemia on lipids as their subsequent oxidation can lead to complications such as nephropathy, neuropathy, and retinopathy in diabetics which can further lead to macrovascular complications in the body.
Methods: The diabetic patients were divided into two groups, based on the presence/absence of secondary microvascular complications, namely, nephropathy, retinopathy, and neuropathy. Two types of cases were included in the study, on the basis of duration, namely, 0–5 years and 5–10 years duration. Blood samples were collected and levels of hemoglobin and glycated hemoglobin were determined. The biochemical parameters, namely, random blood sugar, cholesterol, triglycerides, high-density lipoproteins, low-density lipoproteins (LDLs), and very LDLs were estimated.
Results: The lipid levels altered in diabetic patients, leading to the dyslipidemia and the cumulative effect of hyperglycemia and dyslipidemia leads to the oxidative stress in the body. The increased oxidation of lipids may lead to the occurrence of microvascular complications in the body. Furthermore, dyslipidemia has been found more prevalent in males as compared to females.
Conclusion: Due to the increased prevalence of diabetes in India, funding of this study would suggest that there is a need to accelerate the importance of monitoring lipid levels in diabetes. Diabetic patients should routinely monitor their glycemic status, renal, and lipid profile to avert microvascular complications associated with diabetes mellitus.
2. International Diabetes Federation. IDF Atlas. 7th ed. Brussels: International Diabetes Federation; 2015. Available from: http://www. diabetesatlas.org.
3. Goh K, Tooke J. Abnormalities of the microvasculature. In: Wass J, Shalet S. editors. Oxford Textbook of Endocrinology and Diabetes. Oxford: Oxford University Press; 2002. p. 1749-55.
4. Nerkar D, Mukherjee A, Mehta BK, Banerjee S. Metabolic syndrome associated complications. Intl J Pharm Pharm Sci 2015;7:22-5.
5. American Diabetes Association. Standards of medical care in diabetes. Summary of revisions. Diab Care 2014;39:4-5.
6. Aly EM. Ftir analysis for retina associated with diabetic changes and treatment with oat. Intl J Pharm Pharm Sci 2015;7:277-80.
7. Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol 2014;18:1-14.
8. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010;107:1058-70.
9. Avogaro A, Giorda C, Maggini M, Mannucci E, Raschetti R, Lombardo F, et al. Incidence of coronary heart disease in Type 2 diabetic men and women: Impact of microvascular complications, treatment, and geographic location. Diabetes Care 2007;30:1241-7.
10. Godkar PB, Godkar DP. A Textbook of Medical Laboratory Technology. 3rd ed., Vol. 1. Mumbai: Bhalani Publishing House; 2014.
11. Trinder P. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol 1969;22:158-61.
12. Trivelli LA, Ranney HM, Lai HT. Hemoglobin components in patients with diabetes mellitus. N Engl J Med 1971;284:353-7.
13. Watson D. Determination of cholesterol. Clin Chem Acta 1960;5:371-2.
14. Fossati P. ???. Clin Chem 1982;28:376-7.
15. Jakus V, Rietbrock N. Advanced glycation end-products and the progress of diabetic vascular complications. Physiol Res 2004;53:131-42.
16. Abdel-Gayoum AG. The effect of glycemic control in Type 2 diabetic patients with diabetes-related dyslipidemia. Saudi Med J 2004;25:207-11.
17. Peters AL, Davidson MB, Schriger DL, Hasselblad V. A clinical approach for the diagnosis of diabetes mellitus: An analysis using glycosylated hemoglobin levels. Meta-analysis research group on the diagnosis of diabetes using glycated hemoglobin levels. JAMA 1996;276:1246-52.
18. Kumar PJ, Clark M. Diabetes mellitus and other disorders of metabolism. In: Textbook of Medicine. ???: ???; 2007. p. 1069-122.
19. Dodson PM. Lipoprotein and Diabetes Mellitus. United Kingdom: Castle Publication; 1987.
20. Mulec H, Johnsen SA, Wiklund O, Björck S. Cholesterol: A renal risk factor in diabetic nephropathy? Am J Kidney Dis 1993;22:196-201.
21. Larsson LI, Alm A, Lithner F, Dahlén G, Bergström R. The association of hyperlipidemia with retinopathy in diabetic patients aged 15-50 years in the county of Umeå. Acta Ophthalmol Scand 1999;77:585-91.
22. Tuttle KR, Puhlman ME, Cooney SK, Short R. Urinary albumin and insulin as the predictors of coronary artery disease: An angiopathic study. Am J Kidney Dis 1999;34:918-5.
23. Haffner SM. Sex hormones, obesity, fat distribution, Type 2 diabetes and insulin resistance: Epidemiological and clinical correlation. Int J Obes Relat Metab Disord 2000;24 Suppl 2:S56-8.
24. Zhuang HZ, Hana QQ, Chen HZ. Study of serum lipids and lipoproteins of healthy subjects in shanghai. Chin Med J (Engl) 1986;99:657-9.
25. Walden CE, Knopp RH, Wahl PW, Beach KW, Strandness E Jr. Sex differences in the effect of diabetes mellitus on lipoprotein triglyceride and cholesterol concentrations. N Engl J Med 1984;311:953-9.
26. Beach KW, Strandness DE Jr. Arteriosclerosis obliterans and associated risk factors in insulin-dependent and non-insulin-dependent diabetes. Diabetes 1980;29:882-8.
27. Palumbo PJ, Elveback LR, Chu CP, Connolly DC, Kurland LT. Diabetes mellitus: Incidence, prevalence, survivorship, and causes of death in Rochester, Minnesota, 1945-1970. Diabetes 1976;25:566-73.
28. Mattock MB, Fuller JH, Maude PS, Keen H. Lipoproteins and plasma cholesterol esterification in normal and diabetic subjects. Atherosclerosis 1979;34:437-49.
29. Sarlund H, Laakso M, Pyörälä K, Penttilä I. Association of serum lipids and lipoproteins with plasma C-peptide concentration in non-insulin-dependent diabetic and non-diabetic subjects. Metabolism 1987;36:840-5.
30. Abrams JJ, Ginsberg H, Grundy SM. Metabolism of cholesterol and plasma triglycerides in nonketotic diabetes mellitus. Diabetes 1982;31:903-10.
31. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997;46:3-10.
32. Dabla PK. Renal function in diabetic nephropathy. World J Diabetes 2010;1:48-56.
This work is licensed under a Creative Commons Attribution 4.0 International License.